This article has been corrected. In a previous version, the name "Gentris," was misspelled and the headline was unclear.
NEW YORK, June 24 (GenomeWeb News) - North Carolina biotechnology companies Tranzyme Pharma and Gentris said today that they are collaborating to develop cell lines intended to serve as genetic controls for diagnostic assays used to gauge patients' responses to drug treatments.
Morrisville-based Gentris will provide Tranzyme, located in
In addition, the companies said that they will jointly own the cell lines, and may eventually enter into an additional agreement to commercialize them as genetic controls for FDA-approved diagnostic assays.